Dementia risk and prevention by targeting modifiable vascular risk factors
The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Abstract
The incidence of dementia is expected to double in the next 20 years and will contribute to heavy social and economic burden. Dementia is caused by neuronal loss that leads to brain atrophy years before symptoms manifest. Currently, no cure exists and extensive efforts are being made to mitigate cognitive impairment in late life in order to reduce the burden on patients, caregivers, and society. The most common type of dementia, Alzheimer's disease (AD), and vascular dementia (VaD) often co‐exists in the brain and shares common, modifiable risk factors, which are targeted in numerous secondary prevention trials. There is a growing need for non‐pharmacological interventions and infrastructural support from governments to encourage psychosocial and behavioral interventions. Secondary prevention trials need to be redesigned based on the risk profile of individual subjects, which require the use of validated and standardized clinical, biological, and neuroimaging biomarkers. Multi‐domain approaches have been proposed in high‐risk populations that target optimal treatment; clinical trials need to recruit individuals at the highest risk of dementia before symptoms develop, thereby identifying an enriched disease group to test preventative and disease modifying strategies. The underlying aim should be to reduce microscopic brain tissue loss by modifying vascular and lifestyle risk factors over a relatively short period of time, thus optimizing the opportunity for preventing dementia in the future. Collaboration between international research groups is of key importance to the optimal use and allocation of existing resources, and the development of new techniques in preventing dementia. image This article is part of the Special Issue “Vascular Dementia”.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
MACMAHON, S. (1990) · The Lancet · doi:10.1016/0140-6736(90)90878-9 · Cited by 4,253 · cited 2×
“For example, hypertension has long been known to cause stroke (MacMahon et al. 1990), but hypertension in mid-life ranks as an important risk factor for late cognitive decline (Knopman et al.”
BackgroundGorelick, P. B., Scuteri, A., Black, S. E., DeCarli, C., Greenberg, S. M., Iadecola, C., Launer, L. J., Laurent, S., Lopez, O. L., Nyenhuis, D., et al. (2011) · Stroke · doi:10.1161/str.0b013e3182299496 · Cited by 3,811 · cited 4×
“Just like MCI is a prodromal stage of AD, VCI can cause mild cognitive deficits that can affect multiple cognitive domains and eventually progress to AD/VaD (Gorelick et al. 2011).”
InfluentialNgandu, T., Lehtisalo, J., Solomon, A., Levälahti, E., Ahtiluoto, S., Antikainen, R., Bäckman, L., Hänninen, T., Jula, A., Laatikainen, T., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60461-5 · Cited by 3,689 · cited 6×
“While the FINGER (Ngandu et al. 2015) and multidomain Alzheimer prevention trial (Vellas and Carrie 2014) studies found a reduction in the incidence of dementia, the preDIVA (Prevention of Dementia by Intensive Vascular care) (van Charante et al. 2016) trial failed to find an effect calling attention to several method…”
BackgroundInfluentialBlennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
Staessen, J. A., Fagard, R., Thijs, L., Celis, H., Arabidze, G. G., Birkenhäger, W. H., Bulpitt, C. J., de Leeuw, P. W., Dollery, C. T., Fletcher, A. E., et al. (1997) · The Lancet · doi:10.1016/s0140-6736(97)05381-6 · Cited by 2,989
Alzheimer's Disease Neuroimaging Initiative (ADNI)
Petersen, R. C., Aisen, P. S., Beckett, L. A., Donohue, M. C., Gamst, A. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Shaw, L. M., Toga, A. W., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181cb3e25 · Cited by 2,572 · cited 1×
“Assessing the association of P-Tau/ Ab1-42 ratio to rates of cerebral atrophy is expected to provide an indication of potential contribution of AD to loss of brain volume in the preclinical dementia (Hansson et al. 2006; Fagan et al. 2007; Jack et al. 2008; Petersen et al. 2010).”
BackgroundBallard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61349-9 · Cited by 2,336
Debette, S., & Markus, H. S. (2010) · BMJ · doi:10.1136/bmj.c3666 · Cited by 2,328
Karran, E., Mercken, M., & Strooper, B. D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3505 · Cited by 2,188 · cited 2×
“Quite simply, drugs are administered too late (Karran et al. 2011; Doody et al. 2013; Vellas et al. 2013) most likely because by the time the earliest symptoms appear, substantial and irreversible synaptic and neuronal loss has already occurred in critical brain regions (G omez-Isla et al. 1996;…”
BackgroundReducing Risks for Mental Disorders: Frontiers for Preventive Intervention Research
(1994) · doi:10.17226/2139 · Cited by 2,073 · cited 1×
“Several interventional studies to assess the effects on disease onset are underway in Europe and it is estimated that delaying the onset of dementia by 5 yearswould halve the prevalence of dementia and substantially decrease the number of dementia cases in the community (Mrazek and Haggerty 1994).”
BackgroundCerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · cited 4×
“…of brain atrophy potentially may provide evidence of early treatment modification of disease before detectable clinical outcome (Prins et al. 2014; Salloway et al. 2014; Paquet et al. 2015), and finally, rates of brain atrophy are integral to biological pathways linked to preclinical progression…”
BackgroundInfluentialProfound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease
Gómez-Isla, T., Price, J. L., McKeel Jr., D. W., Morris, J. C., Growdon, J. H., & Hyman, B. T. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-14-04491.1996 · Cited by 1,796 · cited 1×
“…are administered too late (Karran et al. 2011; Doody et al. 2013; Vellas et al. 2013) most likely because by the time the earliest symptoms appear, substantial and irreversible synaptic and neuronal loss has already occurred in critical brain regions (G omez-Isla et al. 1996; Price et al. 2001).”
BackgroundHachinski, V., Iadecola, C., Petersen, R. C., Breteler, M. M., Nyenhuis, D. L., Black, S. E., Powers, W. J., DeCarli, C., Merino, J. G., Kalaria, R. N., et al. (2006) · Stroke · doi:10.1161/01.str.0000237236.88823.47 · Cited by 1,722
Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700 · cited 1×
“Assessing the association of P-Tau/ Ab1-42 ratio to rates of cerebral atrophy is expected to provide an indication of potential contribution of AD to loss of brain volume in the preclinical dementia (Hansson et al. 2006; Fagan et al. 2007; Jack et al. 2008; Petersen et al. 2010).”
BackgroundBaumgart, M., Snyder, H. M., Carrillo, M. C., Fazio, S., Kim, H., & Johns, H. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.05.016 · Cited by 1,660 · cited 8×
“…for vascular disease are also risk factors for AD, such as hypertension (Reitz et al. 2007; Peters et al. 2008; Prince et al. 1996; Kalaria 2012b; Baumgart et al. 2015), hypercholesterolemia (Kivipelto et al. 2001), diabetes mellitus (Cukierman et al. 2005; Qiu et al. 2010; Baumgart et al.…”
BackgroundInfluentialKivipelto, M., Helkala, E.-L., Laakso, M. P., Hänninen, T., Hallikainen, M., Alhainen, K., Soininen, H., Tuomilehto, J., & Nissinen, A. (2001) · BMJ · doi:10.1136/bmj.322.7300.1447 · Cited by 1,618
Brain Infarction and the Clinical Expression of Alzheimer Disease<subtitle>The Nun Study</subtitle>
Snowdon, D. A. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540340047031 · Cited by 1,590 · cited 1×
“One potential explanation proposed is that the combined pathology reduces the threshold for manifesting dementia (Snowdon et al. 1997).”
BackgroundForette, F., Seux, M.-L., Staessen, J. A., Thijs, L., Birkenhäger, W. H., Babarskiene, M.-R., Babeanu, S., Bossini, A., Gil-Extremera, B., Girerd, X., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03086-4 · Cited by 1,441
Neuropathology of older persons without cognitive impairment from two community-based studies
Bennett, D. A., Schneider, J. A., Arvanitakis, Z., Kelly, J. F., Aggarwal, N. T., Shah, R. C., & Wilson, R. S. (2006) · Neurology · doi:10.1212/01.wnl.0000219668.47116.e6 · Cited by 1,336
Obesity and Vascular Risk Factors at Midlife and the Risk of Dementia and Alzheimer Disease
Kivipelto, M., Ngandu, T., Fratiglioni, L., Viitanen, M., Kåreholt, I., Winblad, B., Helkala, E.-L., Tuomilehto, J., Soininen, H., & Nissinen, A. (2005) · Archives of Neurology · doi:10.1001/archneur.62.10.1556 · Cited by 1,291 · cited 4×
“…long been known to cause stroke (MacMahon et al. 1990), but hypertension in mid-life ranks as an important risk factor for late cognitive decline (Knopman et al. 2001), mild cognitive impairment (MCI) (Kivipelto et al. 2005; Reitz et al. 2007), and dementia (Launer et al. 2000; Yamada et al. 2009).”
BackgroundInfluentialEpidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention
Qiu, C., Kivipelto, M., & von Strauss, E. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.2/cqiu · Cited by 1,261
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
O'Brien, J. T., & Thomas, A. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00463-8 · Cited by 1,136
Jack, C. R., Lowe, V. J., Weigand, S. D., Wiste, H. J., Senjem, M. L., Knopman, D. S., Shiung, M. M., Gunter, J. L., Boeve, B. F., Kemp, B. J., et al. (2009) · Brain · doi:10.1093/brain/awp062 · Cited by 1,099
Cognitive decline and dementia in diabetes—systematic overview of prospective observational studies
Cukierman, T., Gerstein, H. C., & Williamson, J. D. (2005) · Diabetologia · doi:10.1007/s00125-005-0023-4 · Cited by 1,049 · cited 3×
“In spite of the vast and continuing literature on the dichotomy between AD and VaD, they share cardiovascular risk factors and frequently co-exist in autopsy studies, supporting the concept that they are closely related disorders (Haan and Wallace 2004; Cukierman et al. 2005; Blennow et al. 2006; Cui et al. 2014).”
BackgroundMidlife blood pressure and dementia: the Honolulu–Asia aging study☆
Launer, L. J., Ross, G. W., Petrovitch, H., Masaki, K., Foley, D., White, L. R., & Havlik, R. J. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00096-8 · Cited by 1,008
Jack, C. R., Lowe, V. J., Senjem, M. L., Weigand, S. D., Kemp, B. J., Shiung, M. M., Knopman, D. S., Boeve, B. F., Klunk, W. E., Mathis, C. A., et al. (2008) · Brain · doi:10.1093/brain/awm336 · Cited by 958
Fagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897
A hitchhiker's guide to diffusion tensor imaging
Soares, J. M., Marques, P., Alves, V., & Sousa, N. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00031 · Cited by 893
Cardiovascular risk factors and cognitive decline in middle-aged adults
Knopman, D., Boland, L. L., Mosley, T., Howard, G., Liao, D., Szklo, M., McGovern, P., & Folsom, A. R. (2001) · Neurology · doi:10.1212/wnl.56.1.42 · Cited by 883
Recent global trends in the prevalence and incidence of dementia, and survival with dementia
Prince, M., Ali, G.-C., Guerchet, M., Prina, A. M., Albanese, E., & Wu, Y.-T. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0188-8 · Cited by 876
Peters, R., Beckett, N., Forette, F., Tuomilehto, J., Clarke, R., Ritchie, C., Waldman, A., Walton, I., Poulter, R., Ma, S., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70143-1 · Cited by 770 · cited 4×
“Epidemiological studies show that several risk factors for vascular disease are also risk factors for AD, such as hypertension (Reitz et al. 2007; Peters et al. 2008; Prince et al. 1996; Kalaria 2012b; Baumgart et al. 2015), hypercholesterolemia (Kivipelto et al. 2001), diabetes mellitus (Cukierman…”
BackgroundInfluentialThe overlap between vascular disease and Alzheimer’s disease - lessons from pathology
Attems, J., & Jellinger, K. A. (2014) · BMC Medicine · doi:10.1186/s12916-014-0206-2 · Cited by 739
Comparing predictors of conversion and decline in mild cognitive impairment
Landau, S. M., Harvey, D., Madison, C. M., Reiman, E. M., Foster, N. L., Aisen, P. S., Petersen, R. C., Shaw, L. M., Trojanowski, J. Q., Jack, C. R., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e8e8b8 · Cited by 616
van Charante, E. P. M., Richard, E., Eurelings, L. S., van Dalen, J.-W., Ligthart, S. A., van Bussel, E. F., Hoevenaar-Blom, M. P., Vermeulen, M., & van Gool, W. A. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30950-3 · Cited by 611
Neuron Number in the Entorhinal Cortex and CA1 in Preclinical Alzheimer Disease
Price, J. L., Ko, A. I., Wade, M. J., Tsou, S. K., McKeel, D. W., & Morris, J. C. (2001) · Archives of Neurology · doi:10.1001/archneur.58.9.1395 · Cited by 596
Casserly, I., & Topol, E. J. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15900-x · Cited by 560
Hippocampal formation glucose metabolism and volume losses in MCI and AD
De Santi, S., de Leon, M. J., Rusinek, H., Convit, A., Tarshish, C. Y., Roche, A., Tsui, W. H., Kandil, E., Boppana, M., Daisley, K., et al. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00230-5 · Cited by 548
Lee, S., Viqar, F., Zimmerman, M. E., Narkhede, A., Tosto, G., Benzinger, T. L. S., Marcus, D. S., Fagan, A. M., Goate, A., Fox, N. C., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24647 · Cited by 542
Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study
Bachman, D. L., Wolf, P. A., Linn, R., Knoefel, J. E., CobbS, J., Belanger, A., D'Agostino, R. B., & White, L. R. (1992) · Neurology · doi:10.1212/wnl.42.1.115 · Cited by 527
Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI
Jack, C. R., Shiung, M. M., Weigand, S. D., O’Brien, P. C., Gunter, J. L., Boeve, B. F., Knopman, D. S., Smith, G. E., Ivnik, R. J., Tangalos, E. G., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000180958.22678.91 · Cited by 492
White matter changes in mild cognitive impairment and AD: a diffusion tensor imaging study
Medina, D., deToledo-Morrell, L., Urresta, F., Gabrieli, J. D. E., Moseley, M., Fleischman, D., Bennett, D. A., Leurgans, S., Turner, D. A., & Stebbins, G. T. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.03.026 · Cited by 492
Kalaria, R. N. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1571-z · Cited by 441
High total cholesterol levels in late life associated with a reduced risk of dementia
Mielke, M. M., Zandi, P. P., Sjögren, M., Gustafson, D., Östling, S., Steen, B., & Skoog, I. (2005) · Neurology · doi:10.1212/01.wnl.0000161870.78572.a5 · Cited by 411
Hypertension and the Risk of Mild Cognitive Impairment
Reitz, C., Tang, M.-X., Manly, J., Mayeux, R., & Luchsinger, J. A. (2007) · Archives of Neurology · doi:10.1001/archneur.64.12.1734 · Cited by 360
Clark, C. M., Xie, S., Chittams, J., Ewbank, D., Peskind, E., Galasko, D., Morris, J. C., McKeel, D. W., Farlow, M., Weitlauf, S. L., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1696 · Cited by 357
Effectiveness of regional DTI measures in distinguishing Alzheimer’s disease, MCI, and normal aging
Nir, T. M., Jahanshad, N., Villalon-Reina, J. E., Toga, A. W., Jack, C. R., Weiner, M. W., & Thompson, P. M. (2013) · NeuroImage: Clinical · doi:10.1016/j.nicl.2013.07.006 · Cited by 348
Chen, J.-H., Lin, K.-P., & Chen, Y.-C. (2009) · Journal of the Formosan Medical Association · doi:10.1016/s0929-6646(09)60402-2 · Cited by 288
Correlations between MRI white matter lesion location and executive function and episodic memory
Smith, E. E., Salat, D. H., Jeng, J., McCreary, C. R., Fischl, B., Schmahmann, J. D., Dickerson, B. C., Viswanathan, A., Albert, M. S., Blacker, D., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e318217e7c8 · Cited by 243
Progression of impairment in patients with vascular cognitive impairment without dementia
Wentzel, C., Rockwood, K., MacKnight, C., Hachinski, V., Hogan, D. B., Feldman, H., Østbye, T., Wolfson, C., Gauthier, S., Verreault, R., et al. (2001) · Neurology · doi:10.1212/wnl.57.4.714 · Cited by 243 · cited 1×
“The early identification of people at risk for cognitive impairment is potentially the single most important approach for prevention or postponement of dementia sequelae to reduce public health costs (Bachman et al. 1992; Petersen et al. 1999; Wentzel et al. 2001; Norton et al. 2014).”
BackgroundBourgeat, P., Chételat, G., Villemagne, V. L., Fripp, J., Raniga, P., Pike, K., Acosta, O., Szoeke, C., Ourselin, S., Ames, D., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181c918b5 · Cited by 220 · cited 2×
“…al. 2014; Salloway et al. 2014; Paquet et al. 2015), and finally, rates of brain atrophy are integral to biological pathways linked to preclinical progression of vascular disease and AD (Hubbard and Anderson 1981; Braak and Braak 1991; Price et al. 2001; Bourgeat et al. 2010; Schott et al. 2010b).”
BackgroundWeston, P. S. J., Simpson, I. J. A., Ryan, N. S., Ourselin, S., & Fox, N. C. (2015) · Alzheimer's Research & Therapy · doi:10.1186/s13195-015-0132-3 · Cited by 214
Is the risk of Alzheimer’s disease and dementia declining?
Langa, K. M. (2015) · Alzheimer's Research & Therapy · doi:10.1186/s13195-015-0118-1 · Cited by 200
Brayne, C., the Cambridge City over-75s Cohort (CC75C) study neuropathology collaboration, Richardson, K., Matthews, F. E., Fleming, J., Hunter, S., Xuereb, J. H., Paykel, E., Mukaetova-Ladinska, E. B., Huppert, F. A., et al. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-1182 · Cited by 191 · cited 2×
“Rapid rates of atrophy differentiate persons with dementia from those without dementia in all age groups (Hubbard and Anderson 1981; Brayne et al. 2009).”
BackgroundGray and white matter changes in Alzheimer's disease: a diffusion tensor imaging study
Rose, S. E., Janke PhD, A. L., & Chalk, J. B. (2008) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.21231 · Cited by 178
APOE Genotype and Neuroimaging Markers of Alzheimer’s Disease: Systematic Review and Meta-Analysis
Liu, Y., Yu, J.-T., Wang, H.-F., Han, P.-R., Tan, C.-C., Wang, C., Meng, X.-F., Risacher, S. L., Saykin, A. J., & Tan, L. (2015) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-307719 · Cited by 152 · cited 1×
“…et al. 2015), smoking (Kivipelto et al. 2001; Chen et al. 2009; Baumgart et al. 2015), Apolipoprotein E e4 isoforms (Pasquier and Leys 1997; Liu et al. 2015; Tosto et al. 2016), obesity (Haan and Wallace 2004; Kivipelto et al. 2005; Qiu et al. 2010; Barnes and Yaffe 2011; Baumgart et al.…”
BackgroundMorphologic diagnosis of “vascular dementia” — A critical update
Jellinger, K. A. (2008) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2008.03.006 · Cited by 150
Vellas, B., Carrillo, M. C., Sampaio, C., Brashear, H. R., Siemers, E., Hampel, H., Schneider, L. S., Weiner, M., Doody, R., Khachaturian, Z., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.03.007 · Cited by 147
Richard, E., Andrieu, S., Solomon, A., Mangialasche, F., Ahtiluoto, S., van Charante, E. P. M., Coley, N., Fratiglioni, L., Neely, A. S., Vellas, B., et al. (2012) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2012.06.012 · Cited by 121 · cited 7×
“studies with long follow-ups (Richard et al. 2012), making such studies fraught with issues related to patient attrition and cost.”
BackgroundInfluentialQiu, C., Xu, W., & Fratiglioni, L. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-091663 · Cited by 107
Richard, E., Jongstra, S., Soininen, H., Brayne, C., Moll van Charante, E. P., Meiller, Y., van der Groep, B., Beishuizen, C. R. L., Mangialasche, F., Barbera, M., et al. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-010806 · Cited by 92
Kantarci, K., Schwarz, C. G., Reid, R. I., Przybelski, S. A., Lesnick, T. G., Zuk, S. M., Senjem, M. L., Gunter, J. L., Lowe, V., Machulda, M. M., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1482 · Cited by 88 · cited 3×
“Amyloid burden in AD is assessed using several amyloid tracers for PET such as Pittsburgh compound B (PiB) [38], 11C-Pittsburg Compound B (11C-PiB) (Kantarci et al. 2014) and 18F-labeled (Jack et al. 2008, 2009).”
BackgroundMethodInfluentialHalliday, G., Ng, T., Rodriguez, M., Harding, A., Blumbergs, P., Evans, W., Fabian, V., Fryer, J., Gonzales, M., Harper, C., et al. (2002) · Acta Neuropathologica · doi:10.1007/s00401-002-0529-5 · Cited by 57 · cited 1×
“1), which contribute to loss of brain cells and brain atrophy years before symptoms are detected: Alzheimer’s disease (AD) and cerebrovasular disease (CVD) (Jellinger et al. 1990; Terry et al. 1991; Halliday et al. 2002; Bennett et al. 2006; Brayne 2007).”
BackgroundYamada, M., Mimori, Y., Kasagi, F., Miyachi, T., Ohshita, T., & Sasaki, H. (2009) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.02.338 · Cited by 24
Cited by
Early-Stage Alzheimer’s Disease Prediction Using Machine Learning Models
Kavitha, C., Mani, V., Srividhya, S. R., Khalaf, O. I., & Tavera Romero, C. A. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.853294 · Cited by 373
A Perspective on Multi-target Drugs for Alzheimer’s Disease
Benek, O., Korabecny, J., & Soukup, O. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.04.008 · Cited by 260
Zhu, H.-Y., Hong, F.-F., & Yang, S.-L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094540 · Cited by 84
Low vision and the risk of dementia: a nationwide population-based cohort study
Paik, J.-S., Ha, M., Jung, Y. H., Kim, G.-H., Han, K.-D., Kim, H.-S., Lim, D. H., & Na, K.-S. (2020) · Scientific Reports · doi:10.1038/s41598-020-66002-z · Cited by 54
Impact of cardiovascular hemodynamics on cognitive aging
Moore, E. E., & Jefferson, A. L. (2021) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.120.311909 · Cited by 49
Metadata
- Authors
- Tariq, S., & Barber, P. A.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2017-09-06
- Volume
- 144
- Issue
- 5
- Pages
- 565-581
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2736594305
- Cited by
- 136
- References
- 70
- FWCI
- 5.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.